Response to Omalizumab as an Add-On Therapy in the Treatment of Allergic Asthma in Adult Chinese Patients—A Retrospective Study

Response to Omalizumab as an Add-On Therapy in the Treatment of Allergic Asthma in Adult Chinese Patients—A Retrospective Study

(a) Background: Omalizumab is an anti-IgE humanized monoclonal antibody marketed in China for the conventional treatment of poorly controlled moderate-to-severe allergic asthma. Numerous clinical trials have demonstrated the effectiveness of omalizumab, but the data from studies in actual clinical t...

Full description

Bibliographic Details
Main Authors:	Na Li, Linfeng Cao, Ming Zhang, Chunyuan Fei, Jingjing Deng
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Vaccines
Subjects:	omalizumab budesonide formoterol immunoglobulin E allergic asthma response
Online Access:	https://www.mdpi.com/2076-393X/10/12/2068

Similar Items

Omalizumab Treatment in Patients with Severe Allergic Asthma
by: Tuğba Songül Tat, et al.
Published: (2017-09-01)

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL
by: Francesco Menzella, MD, et al.
Published: (2023-06-01)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
by: S. M. Snelder, et al.
Published: (2017-07-01)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
by: Serafeim Chrysovalantis Kotoulas, et al.
Published: (2022-01-01)

Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases
by: J. Bousquet, et al.
Published: (2008-04-01)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
by: Tajiri T, et al.
Published: (2023-01-01)

Comparison of efficacy between long-acting beta 2-agonists (formoterol fumarate) and leukotriene-receptor antagonists (montelukast) as add-on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma
by: Sasikala Kumaravel, et al.
Published: (2014-01-01)

Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
by: Just J, et al.
Published: (2021-09-01)

Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry
by: Petr Vaník, et al.
Published: (2020-09-01)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
by: Carlos A. Torres-Duque, et al.
Published: (2022-11-01)

Quantitative CT Metrics for the Prediction of Therapeutic Effect in Asthma
by: Donghai Ma, et al.
Published: (2023-01-01)

Mild bronchial asthma: a modern treatment concept
by: A. V. Emel’yanov, et al.
Published: (2019-12-01)

BRONCHIAL ASTHMA THERAPY IN SMART-REGIME: STUDIES IN REAL CLINICAL PRACTICE
by: R. S. FASSAKHOV
Published: (2016-12-01)

The role of omalizumab in the treatment of adults with severe allergic asthma
by: Sabina Škrgat Kristan
Published: (2013-02-01)

Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases
by: Baihua Xu, et al.
Published: (2024-04-01)

Adherence and quality of life assessment in patients with asthma treatment with budesonide/formoterol via the Elpenhaler device: the COMPLETE study
by: Konstantinos P. Exarchos, et al.
Published: (2022-06-01)

Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis
by: Weikun Chong, et al.
Published: (2023-10-01)

Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma
by: Nicola A. Hanania, MD, et al.
Published: (2022-10-01)

Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap
by: Luisa Ricciardi, et al.
Published: (2022-02-01)

Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study
by: Su N, et al.
Published: (2023-06-01)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
by: Giorgio Walter Canonica, et al.
Published: (2018-11-01)

Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance
by: Noriko Nakamura, et al.
Published: (2021-07-01)

Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma—A Romanian Perspective
by: Elena Camelia Berghea, et al.
Published: (2021-12-01)

Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study
by: Rui Tang, et al.
Published: (2022-07-01)

The effectiveness of target therapy in patients with severe allergic asthma
by: O V Skorokhodkina, et al.
Published: (2019-12-01)

The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment
by: Wei-Chang Huang, et al.
Published: (2021-02-01)

Optimization of therapy of patients with bronchial asthma in conditions of coronavirus infection
by: E. M. Kostina, et al.
Published: (2021-10-01)

The rationale for treating allergic asthma with anti-IgE
by: E. Hamelmann
Published: (2007-09-01)

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy
by: Velling P, et al.
Published: (2011-09-01)

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
by: Canonica GW, et al.
Published: (2020-01-01)

How to evaluate a patient's response to anti-IgE
by: S. T. Holgate
Published: (2007-09-01)

Patient characteristics that can predict response to omalizumab an (Anti-IgE Antibody) for achieving better control of asthmatic patients
by: Nancy M. Abdelaty
Published: (2012-07-01)

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study
by: Hélène Salvator, et al.
Published: (2024-01-01)

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap
by: Ishiura Y, et al.
Published: (2020-02-01)

Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients
by: Hyun-moon Back, et al.
Published: (2020-04-01)

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
by: Susana Rojo-Tolosa, et al.
Published: (2023-04-01)

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
by: Jae-Woo Jung, et al.
Published: (2021-07-01)

Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy
by: Hiroshi Odajima, et al.
Published: (2015-10-01)

Effect of Switching from Salmeterol/Fluticasone to Formoterol/Budesonide Combinations in Patients with Uncontrolled Asthma
by: Taisuke Akamatsu, et al.
Published: (2012-01-01)

Benefits of omalizumab on anxiety and depression in patients with severe asthma
by: Fatih Uzer, et al.
Published: (2018-05-01)